Connect with us

Science

3 Trending Penny Stocks to Add to Your Watchlist Right Now

Add these penny stocks to your trending small-caps watchlist
The post 3 Trending Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

on

Are These Trending Penny Stocks Worth Watching Next Year?

Finding trending penny stocks is one of the best ways that investors can have a chance at making money with small caps. But, just because certain penny stocks are trending doesn’t mean that they are worth buying. 

Now, as 2021 ends, there are plenty of ways to find penny stocks that are trending. This includes looking online at outlets such as Reddit, Twitter, and others. While social sentiment may not have been important only a year ago, now, it is a major cause behind movement with either penny stocks or blue chips. But, investors should keep in mind that when penny stocks are trending, they tend to move frequently, resulting in large intraday price swings. This means that traders can lose money just as quickly as they made it. So, keeping a close eye on what is going on in the stock market and how to take advantage, will be a major asset to your trading. 

[Read More] Top Penny Stocks to Buy Now? Check These 3 Out For the New Year

In addition, understanding how certain factors will impact both the stocks on your watchlist and the industries you’re interested in, will also give you the best chance at making money with penny stocks. As we continue to barrel toward the end of the year, there are plenty of factors to keep track of with the stock market. With that in mind, let’s take a look at three trending penny stocks to add to your watchlist right now. 

3 Trending Penny Stocks to Watch Right Now 

  1. Inspira Technologies Oxy BHN Ltd. (NASDAQ: IINN
  2. Reliance Global Group Inc. (NASDAQ: RELI
  3. Gevo Inc. (NASDAQ: GEVO

Inspira Technologies Oxy BHN Ltd. (NASDAQ: IINN)

While no news came out that is responsible for IINN’s 24% rise in the past five days, it’s clear there is a sizable amount of bullish sentiment behind the company. Before we go into the recent news surrounding IINN stock, it’s worth understanding what the company does. For starters, Inspira Technologies is a medical device company that is focused on respiratory care. Of course, there is a clear tie between this work and the pandemic. 

Right now, the company is in development of an artificial lung device known as the ART, which is for use in those with deteriorating lungs. This could minimize the need for mechanical ventilation, which has become a major issue in the past two years. A few weeks ago, the company announced that it signed a strategic agreement with Innovimed for the deployment of 1,522 ART systems in several countries across Europe. The deal, which could be worth roughly $108 million over a 7-year period, is big news for investors and is likely causing the recent moves with IINN stock. 

“Poland, Czech Republic and Slovakia are very interesting markets for Inspira’s ART device. The extracorporeal membrane oxygenation (ECMO) program for Greater Poland’ takes full advantage of the ECMO perfusion therapy opportunities to promote the health of citizens in the region.” 

The CFO of Inspira, Joe Hayon

With this exciting news in mind, does IINN deserve a spot on your list of penny stocks to watch?

Reliance Global Group Inc. (NASDAQ: RELI) 

One of the bigger gainers of the day so far is RELI stock, which managed to shoot up by over 20% at midday. If you think that is substantial, in the past five days, shares of RELI stock have climbed by more than 88%. This has brought it technically out of penny stocks territory if we consider today’s gain. So, why exactly is RELI stock moving right now? 

Well, with no news coming out of the company today, we can look at an announcement made at the end of last week. The company stated that it engaged in a $20 million private placement with institutional investors. The agreement, which priced shares at around $4.09, should offer the company the capital to fund the recently announced acquisition of Medigap. In addition, it will be able to continue marketing activities related to its 5MinuteInsure.com company. 

[Read More] Short Squeeze Penny Stocks To Buy For Under $5 If You Like Risk

Obviously, the funding itself is big news for the company, however, the acquisition is what investors seem to be interested in. And while it is too soon to say what the full outcome of this will be, it is an exciting prospect. Whether this makes RELI stock worth adding to your penny stocks watchlist or not is up to you.

Penny_Stocks_to_Watch_Reliance

Gevo Inc. (NASDAQ: GEVO) 

At just under $5 per share, GEVO stock is teetering at the penny stock mark. And with a YTD gain of roughly 13.6%, investors are keeping a close eye on the company right now. If you’re not familiar with Gevo, it operates in the renewable energy sector. 

The company focuses on turning carbon and renewable fuel sources into liquid hydrocarbons. These can then be used as normal fuel for vehicles such as cars and jets. In the past few weeks, Gevo has been focused on adding new personal such as Staci Bogue-Bucholz as its Site and Process Optimization leader and Lisa Walker as its new Assistant General Counsel. 

Outside of this, we also have to consider that there is a major amount of emphasis on the renewable energy market right now. And, many investors are showing bullish interest in the long-term future of this market. So, this could help to explain the recent bullish sentiment with GEVO stock. And, the new additions to its team help to show that the company is working hard to continue growing. With all of that in mind, do you think that GEVO stock is worth buying right now or not?

Penny_Stocks_to_Watch_Gevo

Which Penny Stocks Are on Your Watchlist As 2021 Ends?

While finding trending penny stocks to buy can be challenging, there are plenty to choose from. As a result of the sheer amount of trending penny stocks out there, investors need to be sure to do the proper research into the stocks they are interested in. 

[Read More] 5 Penny Stocks To Buy In 2021 That Turned $2,500 Into $31,530

Right now, there are also a long list of factors that are impacting the stock market. And, all of these should be taken into account for investors. So, as we continue to barrel through 2021 and right into 2022, which penny stocks are on your watchlist right now?


If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!


The post 3 Trending Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Science

Emergent Health (OTCMKTS: EMGE) Up Big and Getting Noticed by Investors After Biotech Signs LOI to Acquire Fusion Specialty Pharmacy

Emergent Health (OTCMKTS: EMGE) is making an explosive move up the charts after the Company reported it has executed a Binding Letter of Intent to acquire…

Published

on

Emergent Health (OTCMKTS: EMGE) is making an explosive move up the charts after the Company reported it has executed a Binding Letter of Intent to acquire Fusion Specialty Pharmacy subject to financing and execution of certain definitive agreements. Fusion generated $3,801,497 in 2021 Revenues, an approximate 100% increase from 2020 Revenues of $1,971,599. The acquisition is projected to close during the 3rd quarter of this year. 

Fusion Specialty Pharmacy is a nationally accredited compounding pharmacy licensed in 27 states and located in St. George, Utah dedicated to formulating creative, individualized, and compounded medications that can improve compliance, maximize the potential for therapeutic success, and reduce the overall cost of healthcare. One of Fusions goals is to offer a personalized service to their patients and help them understand their core ailment. This allows Fusion to work closely with their physicians and create a customized formulation. Fusion offers the personalized attention that other pharmacies are unable to offer due to their business environment. 

Subscribe To Our 100% Free Penny Stock Newsletter!

Emergent Health (OTCMKTS: EMGE) Curates Companies and Products, Develops and Sells in the Regenerative Health Space … Its products comprise ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. PharmaZu Corp., its newly acquired subsidiary, is a pure play, e-commerce products and service provider focused on The Pet Community, Pet Pharmacy and Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. 

Earlier this year EMGE executed an agreement with DynaCord, LLC. of Baton Rouge, LA for the co-development and exclusive marketing and distribution of a line of various injectable and topical biologic Exosomes for treatment of arthritis, joint care, wound care, and inflammation for Pets. 

The Human Exosomes market recorded revenue of approximately USD 174.04 million in 2020 and is projected to register a CAGR of 27.89% during the forecast period of 2018 – 2026. During the current period of the COVID-19 pandemic, there is a rising demand for Exosomes, which is driving the market growth. In 2020, Dog ownership increased 54%, Pet Industry sales topped $100 billion dollars and Industry forecasts say pet spending will exceed $275 billion by 2030.

To Find out the inside Scoop on EMGE Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

 

According to the Agreement, DynaCord shall be the exclusive manufacturer and PharmaZu the exclusive marketer and distributor to retail, veterinarians direct-to-consumer of a line of Pet related Exosome products. Exosomes are small vesicles that are secreted by stem cells. Exosomes have been shown to be key mediators of cell-to-cell communication, delivering a distinct cargo of lipids, proteins and nucleic acids that reflects their cell of origin. The Exosomes released by regenerative cells such as stem cells, for example, are indicated as potent drivers of healing and repair. Whereas Exosomes secreted from diseased cells could be used to detect and diagnose conditions such as cancers at their earliest and most readily treatable phase. Exosomes offer a potential new paradigm in the diagnosis and treatment of disease. A broad range of Exosome-based biomedical applications are now beginning to be assessed in clinical trials. 

Dynacord is led by Keyon Janini. Janini has spent the majority of his life in the medical industry. He co-founded and helped develop DMS, a telemedicine platform. He then went on the become the president of Neuro Technology Institute, an intraoperative monitoring company. Most recently, he founded and grew 5 Leaf Laboratories, a hemp product manufacturer and distributor. He has spent the last 5 years actively navigating the regulatory body surrounding the stem cell industry. 

DynaCord is a leading Exosome biotechnology research and manufacturer, specializing in the development and production of Umbilical Cord Derived Mesenchymal Stem Cell (MSC) Exosome products. 

On the Fusions LOI Koby Taylor CEO of Fusion stated, “I’m looking forward to joining the Emergent Health team and anxious to add my skills and experience to enhancing the overall Emergent Health family of products.” 

James Zimbler, CEO of Emergent added, “We’re very excited about the upcoming acquisition of Fusion Specialty Pharmacy. Fusion will allow us to greatly expand our on-line pet-med offerings through our subsidiary, PharmaZu, Inc. Fusion will also allow Emergent to fulfill orders in all states.” 

Adam Brooks, President of PharmaZu, Inc., stated, “With the addition of Fusion, we will obtain licensure in all 50 States which will allow PharmaZu the ability to fill prescriptions nationwide, greatly expanding the reach of PharmaZu’s pet medicine business.” 

For More on EMGE Subscribe Right Now!

Currently trading at a $600,000 market valuation EMGE has 75,851,111 shares outstanding out of 200 million authorized, 50,327,516 of which are restricted leaving just 25,523,595 free trading shares and float of 4,083,089 shares. EMGE is an exciting story developing in small caps; while the Company has little assets, they do have some revenues and have just $283,000 in total liabilities. The stock is up big after the Company reported it has executed a binding LOI to acquire Fusion Specialty Pharmacy subject to financing and execution of certain definitive agreements. Fusion generated $3,801,497 in 2021 Revenues, an approximate 100% increase from 2020 Revenues of $1,971,599. The acquisition is projected to close during the 3rd quarter of this year. Biotech’s are particularly explosive and with EMGE shares structure and pending acquisition big things could be in the works here. Microcapdaily will be covering EMGE so make sure you subscribe to Microcapdaily right now so you don’t miss it. 

Subscribe To Our 100% Free Penny Stock Newsletter!

Disclosure: we hold no position in EMGE either long or short and we have not been compensated for this article.

The post Emergent Health (OTCMKTS: EMGE) Up Big and Getting Noticed by Investors After Biotech Signs LOI to Acquire Fusion Specialty Pharmacy first appeared on Micro Cap Daily.

Read More

Continue Reading

Science

University of Kentucky researchers develop online portal to show how biases in RNA sequences affect gene expression

LEXINGTON, Ky. (June 29, 2022) — A recent publication from researchers at the University of Kentucky explains the importance of identifying and understanding…

Published

on

LEXINGTON, Ky. (June 29, 2022) — A recent publication from researchers at the University of Kentucky explains the importance of identifying and understanding how differences between tissues and cells alter gene expression without changing the underlying genetic code.

Credit: Pete Comparoni | University of Kentucky Photo

LEXINGTON, Ky. (June 29, 2022) — A recent publication from researchers at the University of Kentucky explains the importance of identifying and understanding how differences between tissues and cells alter gene expression without changing the underlying genetic code.

Introductory biology classes teach that DNA is transcribed into RNA, which is then translated into proteins. However, many cellular processes affect how quickly transcription and translation occur. Gene expression looks at the differences in RNA concentrations within a cell, and it can help scientists know which genes are active within that tissue or cell.

“Changes in gene expression can significantly affect various diseases and disease trajectories,” said Justin Miller, Ph.D., assistant professor in the UK College of Medicine’s Department of Pathology and Laboratory Medicine.

Miller, who is also affiliated with the Sanders-Brown Center on Aging and Biomedical Informatics, says he and his colleagues previously developed the first algorithm to identify ramp sequences from a single gene sequence. Through their recent work, Miller and fellow UK co-authors Mark Ebbert, Ph.D., and Matthew Hodgman created an online version of that algorithm and showed that ramp sequences change between tissues and cells without changing the RNA sequence.

A ramp sequence is part of the RNA sequence that slows translation at the beginning of the gene by using codons (sequences of three DNA or RNA nucleotides) that are not easily translated. Ramp sequences counterintuitively increase overall gene expression by evenly spacing the translational machinery and preventing collisions later in translation.

In their recent publication in NAR Genomics and Bioinformatics, the researchers present the first comprehensive analysis of tissue- and cell type-specific ramp sequences and report more than 3,000 genes with ramp sequences that change between tissues and cell types, which correspond with increased gene expression within those tissues and cells.

“This research is the first time that variable ramp sequences have been described. Our comprehensive web interface allows other researchers to creatively explore ramp sequences and gene expression,” said Miller.

The research team says this work is important because while there are multiple ways for our RNA to encode the same proteins, the specific RNA sequence is important to regulate protein and RNA levels.

“Essentially, a ramp sequence works like an on-ramp to a freeway so that ribosomes do not crash into each other, but the length and speed limit of that onramp can change depending on the cell and the available resources within that cell,” Miller explained.

He says he enjoyed working on this project not only with his colleagues at UK but as well as his former colleagues at Brigham Young University and his brother, Kyle Miller, at Utah Valley University. Together, the group created a web interface for people to see how ramp sequences correspond with human and COVID-19 gene expression in different tissues and cells.

Miller says he believes this work will eventually impact patient care. “We created an online interface for researchers to query all human genes and see if a specific gene has a ramp sequence in a given tissue and how that gene is expressed within that tissue,” said Miller. “We also show that various COVID-19 genes and human entry factors for COVID-19 have ramp sequences that change between different tissues. Ramp sequences are much more likely to occur in tissues where the virus is known to proliferate.”

So, the researchers believe that COVID-19 genes have genetic biases (ramp sequences) that allow them to use the available cellular machinery to increase their expression. “Our research may help us better predict which tissues and cells new viruses will infect and also provides a potential therapeutic target to regulate tissue-specific gene expression without changing the translated protein,” said Miller.

Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers P30AG072946 and R01AG068331, and the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM138636. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This work was also funded by the BrightFocus Foundation, under awards A2020118F and A2020161S, and the Alzheimer’s Association, under award 2019-AARG-644082.

The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity, and INSIGHT into Diversity recognized us as a Diversity Champion four years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. UK has been judged a “Great College to Work for” three years in a row, and UK is among only 22 universities in the country on Forbes’ list of “America’s Best Employers.”  We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for five straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.


Read More

Continue Reading

Science

Advancing Diagnostics for Infectious Diseases

With an ever-expanding menu of assays and products that are germane to the precision medicine landscape we are delighted to be producing this informative…

Published

on

View eBook
 

Prior to the pandemic, most folks outside of the industry wouldn’t have been familiar with the term reagent. The word, much like PCR, has now become part of common parlance. For those of us immersed in the world of diagnostic assays we know only too well how important reagents are in the process of identifying disease. They are truly an indispensable cog in the life science wheel of productivity. These may take different forms and guises depending on the task at hand but at their heart they serve to do one thing—to provide critical scientific answers in the pursuit of propelling research forward. Yet, in order to do that they need to be produced to the highest quality and reproducibility. Producing highly specified antibodies, for example, is no trivial task and takes careful planning and execution. Custom manufacturer Fortis Life Sciences, powered by a family of leading life science brands, has been at the forefront of producing premium, custom configured products and services to clients across a spectrum of disciplines for a number of years, spanning a broad portfolio of research and commercial applications. Their unrivalled expertise in the design, development and manufacturing of high-quality custom enzymes combined with a tailored, collaborative approach ensures your infectious disease molecular diagnostic assay will be primed for configuration to the exact specifications you need.

With an ever-expanding menu of assays and products that are germane to the precision medicine landscape we are delighted to be producing this informative eBook in partnership with Fortis. We hope it will give you a snapshot into the world of custom reagent manufacturing with a particular focus on infectious disease applications.

 

Sponsored by:

The post Advancing Diagnostics for Infectious Diseases appeared first on Inside Precision Medicine.

Read More

Continue Reading

Trending